Veeva Systems (VEEV) has signed Biogen (BIIB) and Regeneron Pharmaceuticals (REGN) as new users for its Veeva Vault CRM platform, according to Tuesday statements from Veeva.
No financial details were disclosed.
Biogen will use Veeva Vault CRM as its agentic commercial foundation to deliver drugs to patients, while Regeneron plans to use the platform to generate commercial evidence that will back treatment adoption, Veeva said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.